title: Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
authors.forename: S Matthijs
authors.initials: SM
authors.lastname: Boekholdt
authors.forename: Robbert J
authors.initials: RJ
authors.lastname: de Winter
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001547:Benzaldehydes / Q000627:therapeutic use; D002317:Cardiovascular Agents; D003327:Coronary Disease / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D010091:Oximes / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
chemical_list: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000893:Anti-Inflammatory Agents; D001547:Benzaldehydes; D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D010091:Oximes; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides